{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:48:51Z","timestamp":1787431731358,"version":"build-2736575974"},"reference-count":28,"publisher":"Archives of Endocrinology and Metabolism","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,12]]},"DOI":"10.20945\/2359-3997000000609","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:22:22Z","timestamp":1684160542000},"source":"Crossref","is-referenced-by-count":8,"title":["Prediction for recurrence following antithyroid drug therapy for Graves\u2019 hyperthyroidism"],"prefix":"10.20945","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-2754","authenticated-orcid":false,"given":"Huan","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4709-2622","authenticated-orcid":false,"given":"Wen Bo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6485-6006","authenticated-orcid":false,"given":"Zi Dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-922X","authenticated-orcid":false,"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20230515102219_B1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-60327-285-8_44","volume-title":"Diagnostic criteria in autoimmune diseases","author":"Menconi","year":"2008","unstructured":"1 Menconi F, Oppenheim YL, Tomer Y. Graves disease. Diagnostic criteria in autoimmune diseases. Springer; 2008. p. 231-5."},{"issue":"9","key":"key20230515102219_B2","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"Sundaresh","year":"2013","unstructured":"2 Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, et al. Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98(9):3671-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20230515102219_B3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MED.0000000000000088","article-title":"Relapse following antithyroid drug therapy for Graves\u2019 hyperthyroidism","volume":"21","author":"Laurberg","year":"2014","unstructured":"3 Laurberg P, Krejbjerg A, Andersen SL. Relapse following antithyroid drug therapy for Graves\u2019 hyperthyroidism. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):415-21.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"key20230515102219_B4","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves\u2019 Hyperthyroidism","volume":"101","author":"Vos","year":"2016","unstructured":"4 Vos XG, Endert E, Zwinderman AH, Tijssen JGP, Wiersinga WM. Predicting the Risk of Recurrence Before the Start of Antithyroid Drug Therapy in Patients With Graves\u2019 Hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381-9.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20230515102219_B5","doi-asserted-by":"crossref","first-page":"662.e4","DOI":"10.1016\/j.clinthera.2020.01.022","article-title":"Risk Factors for the Relapse of Graves\u2019 Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis","volume":"42","author":"Shi","year":"2020","unstructured":"5 Shi H, Sheng RR, Hu YF, Liu XY, Jiang L, Wang ZM, et al. Risk Factors for the Relapse of Graves\u2019 Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. Clin Ther. 2020;42(4):662-75.e4.","journal-title":"Clin Ther"},{"issue":"12","key":"key20230515102219_B6","doi-asserted-by":"crossref","first-page":"4873","DOI":"10.1210\/jc.2006-1402","article-title":"Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype","volume":"91","author":"Manji","year":"2006","unstructured":"6 Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK, et al. Influences of age, gender, smoking, and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-80.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"key20230515102219_B7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1210\/jc.2018-01738","article-title":"Age May Influence the Impact of TRAbs on Thyroid Function and Relapse-Risk in Patients With Graves Disease","volume":"104","author":"Bano","year":"2019","unstructured":"7 Bano A, Gan E, Addison C, Narayanan K, Weaver JU, Tsatlidis V, et al. Age May Influence the Impact of TRAbs on Thyroid Function and Relapse-Risk in Patients With Graves Disease. J Clin Endocrinol Metab. 2019;104(5):1378-85.","journal-title":"J Clin Endocrinol Metab"},{"key":"key20230515102219_B8","first-page":"100207","article-title":"Graves\u2019 disease and mental disorders","volume":"19","author":"Fukao","year":"2019","unstructured":"8 Fukao A, Takamatsu J, Arishima T, Tanaka M, Kawai T, Okamoto Y, et al. Graves\u2019 disease and mental disorders. J Clin Transl Endocr. 2019;19:100207.","journal-title":"J Clin Transl Endocr"},{"issue":"3","key":"key20230515102219_B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cen.13543","article-title":"Optimal iodine supplementation during antithyroid drug therapy for Graves\u2019 disease is associated with lower recurrence rates than iodine restriction","volume":"88","author":"Huang","year":"2018","unstructured":"9 Huang HB, Shi YX, Liang B, Cai HY, Cai QY, Lin RH. Optimal iodine supplementation during antithyroid drug therapy for Graves\u2019 disease is associated with lower recurrence rates than iodine restriction. Clin Endocrinol (Oxf). 2018;88(3):473-8.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"12","key":"key20230515102219_B10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1089\/thy.2015.0195","article-title":"Outcomes in Relapsed Graves\u2019 Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment","volume":"25","author":"Villagelin","year":"2015","unstructured":"10 Villagelin D, Romaldini JH, Santos RB, Milkos ABBP, Ward LS. Outcomes in Relapsed Graves\u2019 Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid. 2015;25(12):1282-90.","journal-title":"Thyroid"},{"issue":"4","key":"key20230515102219_B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","unstructured":"11 Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86.","journal-title":"Eur Thyroid J"},{"issue":"6","key":"key20230515102219_B12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/jsr.12594","article-title":"European guideline for the diagnosis and treatment of insomnia","volume":"26","author":"Riemann","year":"2017","unstructured":"12 Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26(6):675-700.","journal-title":"J Sleep Res"},{"issue":"5","key":"key20230515102219_B13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1046\/j.1365-2265.2003.01625.x","article-title":"The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves\u2019 disease","volume":"58","author":"Fukao","year":"2003","unstructured":"13 Fukao A, Takamatsu J, Murakami Y, Sakane S, Miyauchi A, Kuma K, et al. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves\u2019 disease. Clin Endocrinol (Oxf). 2003;58(5):550-5.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"key20230515102219_B14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1751-0759-5-9","article-title":"The thyroid function of Graves\u2019 disease patients is aggravated by depressive personality during antithyroid drug treatment","volume":"5","author":"Fukao","year":"2011","unstructured":"14 Fukao A, Takamatsu J, Kubota S, Miyauchi A, Hanafusa T. The thyroid function of Graves\u2019 disease patients is aggravated by depressive personality during antithyroid drug treatment. Biopsychosoc Med. 2011;5(1):9.","journal-title":"Biopsychosoc Med"},{"issue":"9","key":"key20230515102219_B15","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1055\/s-0032-1323807","article-title":"Mental Health Status and Factors that Influence the Course of Graves\u2019 Disease and Antithyroid Treatments","volume":"120","author":"Chen","year":"2012","unstructured":"15 Chen DY, Schneider PF, Zhang XS, He ZM, Jing J, Chen TH. Mental Health Status and Factors that Influence the Course of Graves\u2019 Disease and Antithyroid Treatments. Exp Clin Endocr Diab. 2012;120(9):524-8.","journal-title":"Exp Clin Endocr Diab"},{"key":"key20230515102219_B16","first-page":"247","article-title":"Related factors in predicting relapse of Graves\u2019 disease after treatment with antithyroid drugs","volume":"25","author":"Lan","year":"2009","unstructured":"16 Lan L, Teng WP, Shi BY, Liu XJ, Li H, Liu J, et al. Related factors in predicting relapse of Graves\u2019 disease after treatment with antithyroid drugs. Chin J Endocrinol Metab. 2009;25:247-9.","journal-title":"Chin J Endocrinol Metab"},{"issue":"3","key":"key20230515102219_B17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2265.1984.tb03466.x","article-title":"Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves\u2019 disease?","volume":"21","author":"Madec","year":"1984","unstructured":"17 Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat-Stefanutti A, Orgiazzi J, et al. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves\u2019 disease? Clin Endocrinol (Oxf). 1984;21(3):247-55.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"key20230515102219_B18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/thy.2006.16.295","article-title":"Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period","volume":"16","author":"Carella","year":"2006","unstructured":"18 Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves\u2019 disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and\/or thyroid response modify during the observation period. Thyroid. 2006;16(3):295-302.","journal-title":"Thyroid"},{"issue":"3","key":"key20230515102219_B19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/thy.1997.7.369","article-title":"Clinical features of patients with Graves'disease undergoing remission after antithyroid drug treatment","volume":"7","author":"Vitti","year":"1997","unstructured":"19 Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves'disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-75.","journal-title":"Thyroid"},{"issue":"3","key":"key20230515102219_B20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1055\/s-0043-100116","article-title":"MiR-346 and TRAb as Predicative Factors for Relapse in Graves\u2019 Disease Within One Year","volume":"49","author":"Li","year":"2017","unstructured":"20 Li JH, Cai YW, Sun XH, Yao DZ, Xia JY. MiR-346 and TRAb as Predicative Factors for Relapse in Graves\u2019 Disease Within One Year. Horm Metab Res. 2017;49(3):180-4.","journal-title":"Horm Metab Res"},{"issue":"2","key":"key20230515102219_B21","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12020-019-01987-w","article-title":"When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves\u2019 disease be discontinued?","volume":"65","author":"Park","year":"2019","unstructured":"21 Park S, Song E, Oh HS, Kim M, Jeon MJ, Kim WG, et al. When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves\u2019 disease be discontinued? Endocrine. 2019;65(2):348-56.","journal-title":"Endocrine"},{"issue":"11","key":"key20230515102219_B22","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1172\/JCI21334","article-title":"Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody","volume":"113","author":"Ando","year":"2004","unstructured":"22 Ando T, Latif R, Davies TF. Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody. J Clin Invest. 2004;113(11):1589-95.","journal-title":"J Clin Invest"},{"issue":"1","key":"key20230515102219_B23","first-page":"90","article-title":"Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves\u2019 disease","volume":"84","author":"Costagliola","year":"1999","unstructured":"23 Costagliola S, Morgenthaler NG, Hoermann R, Badenhoop K, Struck J, Freitag D, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves\u2019 disease. J Clin Endocrinol Metab. 1999;84(1):90-7.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"key20230515102219_B24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2265.2008.03192.x","article-title":"Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves\u2019 hyperthyroidism: a prospective study","volume":"69","author":"Vos","year":"2008","unstructured":"24 Vos XG, Smit N, Endert E, Tijssen JGP, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves\u2019 hyperthyroidism: a prospective study. Clin Endocrinol (Oxf). 2008;69(2):311-7.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"key20230515102219_B25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMra042972","article-title":"Antithyroid drugs","volume":"352","author":"Cooper","year":"2005","unstructured":"25 Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-17.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20230515102219_B26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/eje.1.01993","article-title":"A systematic review of drug therapy for Graves\u2019 hyperthyroidism","volume":"153","author":"Abraham","year":"2005","unstructured":"26 Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves\u2019 hyperthyroidism. Eur J Endocrinol. 2005;153(4):489-98.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"key20230515102219_B27","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/eje.1.01904","article-title":"Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine","volume":"152","author":"Azizi","year":"2005","unstructured":"27 Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695-701.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"key20230515102219_B28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/17446651.1.1.91","article-title":"Antithyroid drug therapy of Graves\u2019 hyperthyroidism: realistic goals and focus on evidence","volume":"1","author":"Laurberg","year":"2006","unstructured":"28 Laurberg P, Andersen S, Karmisholt J. Antithyroid drug therapy of Graves\u2019 hyperthyroidism: realistic goals and focus on evidence. Expert Rev Endocrinol Metab. 2006;1(1):91-102.","journal-title":"Expert Rev Endocrinol Metab"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:22:48Z","timestamp":1684160568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/prediction-for-recurrence-following-antithyroid-drug-therapy-for-graves-hyperthyroidism\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5,12]]}},"alternative-id":["10.20945\/2359-3997000000609"],"URL":"https:\/\/doi.org\/10.20945\/2359-3997000000609","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"e000609"}}